+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Transcription and Translation in Health and Disease

  • Book

  • February 2023
  • Elsevier Science and Technology
  • ID: 5646529

Transcription and Translation in Health and Disease provides a detailed overview of the regulators underlying transcription and translation in relation to a variety of human diseases and disorders. Beginning with an introduction into the current perspectives relating to these processes in human disease, the book expands to focus on specific mechanisms underlying conditions such as arthritis, cancer, neurological disorders, diabetes and cardiovascular disease. This book considers RNA processing and related mechanisms in eukaryotes including RNA splicing, RNA binding proteins, RNA interference, microRNAs, RNA editing, transcription factors, RNAi screening, CRISPR activation, CRISPR-Cas9 interference, and post-translational modifications.

It provides a structured and detailed overview of the various regulators underlying molecular processes and their impact on health and disease, equipping readers with the necessary knowledge for further investigation in the areas of treatment and therapeutic intervention.

Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.

Table of Contents

Section I: Introduction 1. Current perspectives on transcription and translational regulators in Health and diseases 2. Role of alternative splicing in health and diseases

Section II: Transcriptional and translational regulators in cancer 3. Transcriptional regulation in cancer progression 4. Role of transcriptional and post-transcriptional regulation of sphingolipid genes in molecular heterogeneity of breast cancer 5. Who dictates and when: Genetic and epigenetic dictatorships in breast cancer response and resistance to therapy 6. CRISPR/Cas9 mediated regulation in cancer 7. Biomarkers for Diagnosis, Prognosis, Treatment of Gastro-Intestinal cancer 8. Regulation of post-transcriptional events by RNA-binding proteins 9. The language of post-translational modifications in cancers and other diseases 10. Ubiquitin proteasome system-mediated regulation of protein function and stability 11. Post-transcriptional regulations in epithelial-tomesenchymal transition and endothelial-to-mesenchymal transitions

Section III: Transcriptional and translation regulators of other diseases 12. Noncoding RNAs in Diabetes 13. MicroRNAs as epigenetic regulators for gut microbiome 14. Cross talk between miRNAs and epigenetics during braindevelopment and neurological diseases 15. The role of non-coding RNAs in rheumatoid arthritis 16. Role of miRNA in autoimmune and inflammatory skin diseases 17. Current Advances in Cancer Prevention and Treatment by Natural Products 18. Therapeutic inhibition of pro-inflammatory cytokins by phytochemicals in osteoarthritis 19. Redox Signaling and Cardiovascular Disease: New Paradigms and discoveries

Section IV: Therapeutics 20. Modulation of epigenetic enzymes by natural agents 21. Inhibitors targeting epigenetic modifications in cancer 22. Drug rechanneling a new paradigm for cancer treatment

Authors

Manoj Garg Associate Professor, Amity Institute of Molecular Medicine and Stem Cell Research (AIMMSCR), Amity University, Noida, India. Dr. Manoj Garg completed his PhD at the National Institute of Immunology (NII), New Delhi and University of Rajasthan, Jaipur, India. He joined as a Research Scientist at the Cancer Science Institute (CSI), National University of Singapore, Singapore in 2010 and extensively worked on cutting-edge technologies including next-generation sequencing of both DNA and RNA, shRNA library screening, drug screening in different subtypes of Acute myeloid leukemia (AML), Acute Lymphocytic leukemia (ALL), esophageal squamous cell carcinoma, pancreatic carcinoma, anaplastic thyroid carcinoma, and liposarcoma. In 2016, Dr. Garg was awarded Ramalingaswami Fellowship and returned to India and joined as an Assistant Professor at Cancer Institute, Chennai. He received the Early Career Research Award from Science Engineering and Research Board (SERB), GOI in 2017. Dr. Garg has published his research in a range of well-reputed scientific journals and serves as an editor for various international journal. Gautam Sethi Associate Professor, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. Dr. Gautam Sethi is a tenured Associate Professor in Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore. The focus of his research over the past few years has been to elucidate the mechanism(s) of activation of oncogenic transcription factors by carcinogens and inflammatory agents and the identification of novel inhibitors of these proteins for prevention of and therapy for cancer. The findings of his research work have so far resulted several publications in high impact factor peer reviewed journals and many international awards. He also serves as an editorial board member for over more than 15 international journals Amit Kumar Pandey Assistant Professor, Amity Institute of Biotechnology, Amity University Haryana, India. Dr. Amit Kumar Pandey completed his postdoctoral training at the Cancer Science Institute of Singapore, National University of Singapore, Singapore where he worked on exploring the role of miRNAs in epigenetic regulation of metastatic breast cancer, and Max Delbruck Center for Molecular Medicine, Berlin, Germany where he worked on exploring the role of non-coding RNAs in metabolism. Dr. Pandey has been working in the field of non-coding RNAs for the last 12 years. He has worked extensively in molecular and cell biology, cell signaling, next generation sequencing. For the last 3 years Dr. Pandey has been working as Assistant professor and running 4 research grants from various govt. agencies as principal investigator. Dr. Pandey currently serves as editor of PLOS One and review editor of Frontiers in Molecular Biosciences.